View Latest Medical and Pharma Bids and Tenders

Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dapagliflozin + Metformin, Atc A10Bd15 (Obo) For The Period 01.10.2024 - 30.09.2026

Medicinal Preparations Containing Metformin, Semaglutide, Sitagliptin And Linagliptin

Conclusion Of Non-Exclusive Discount Agreements According To § 130 A Paragraph 8 Sgb V For Drugs With The Active Ingredient Combination Sitagliptin + Metformin

Conclusion Of Non-Exclusive Discount Agreements According To § 130 A Paragraph 8 Sgb V For Drugs With The Active Ingredient Vildagliptin + Metformin

Conclusion Of Non-Exclusive Discount Agreements According To § 130 A Paragraph 8 Sgb V For Drugs With The Active Ingredient Combination Sitagliptin + Metformin

Conclusion Of Non-Exclusive Discount Agreements According To Section 130A Paragraph 8 Sgb V For Drugs With The Active Ingredient Metformin And Sitagliptin (A10Bd07) As Part Of A So-Called Open House Model.

Medicinal Preparations Containing Metformin, Semaglutide, Sitagliptin And Linagliptin

Metformin

Dapagliflozin And Metformin (Xigduo)

Open House Original Discount Agreements 2023-20 - Metformin/Dapagliflozin (Drug Combination)